Recruiting

Combining targeted drug with focused tumor treatment for advanced lung cancer

Plain-English translation of NCT06620835 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether people with advanced lung cancer (that has an ALK gene mutation) benefit more when they receive Brigatinib combined with focused treatment aimed directly at remaining tumors. The study will check whether adding these focused treatments—like surgery or radiation—at the time when Brigatinib is working best improves outcomes. About 45 people with this specific type of lung cancer will participate across several hospitals in France.

Right now, people with this type of advanced lung cancer take the medication for as long as it works, but we don't know if adding focused treatments to remaining tumors at the best time improves survival and quality of life. This trial is designed to answer that question.

Do you qualify?

You likely qualify if…

you are 18 years or older and have been diagnosed with advanced lung cancer (stage 3 or 4) with an ALK gene rearrangement
your cancer has not been treated with this type of targeted drug before
you have been taking Brigatinib for 3 to 9 months and your cancer has either shrunk or stopped growing
you have five or fewer tumors spread to other parts of your body, with no more than two tumors in any one organ
all of your remaining tumors can be treated with surgery, radiation, or heat-based ablation, as confirmed by the study doctors

You likely don't qualify if…

you have lung cancer without an ALK gene mutation
you have a neuroendocrine tumor (a rare type of lung cancer)
you have untreated or unstable brain tumors causing symptoms
you have had another cancer in the past 5 years (except certain skin cancers or early cervical cancer)
your liver, kidney, or blood cell counts are not functioning well enough, as shown by blood tests

What participation looks like

If you qualify, you will continue taking the medication and receive one of the focused treatments (surgery, radiation, or heat ablation) to remove remaining tumors. You will then visit the clinic every 8 weeks for the first year, and every 12 weeks after that, for up to 3 years. Each visit will include check-ups and tests to see how well the treatment is working and to monitor for any side effects.

Combining targeted drug with focused tumor treatment for advanced lung cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(27 sites)